Antiviral efficacy of LNP-delivered IFN-α14-ApoAI mRNA for chronic hepatitis B
Qunling Yang, Qiang Li, Jie Cao, Conglin Zhao, Mengxin Lu, Shuangshuang Sun, Mingsheng Chen, Chong Chen, Yuxian Huang, Shuai Tao, Liang Chen · 2026
Read Antiviral efficacy of LNP-delivered IFN-α14-ApoAI mRNA for chronic hepatitis B by Qunling Yang, Qiang Li, Jie Cao, Conglin Zhao, Mengxin Lu, Shuangshuang Sun, Mingsheng Chen, Chong Chen, Yuxian Huang, Shuai Tao, Liang Chen (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13272520.txt.
Description
Qunling Yang and co-authors tested a new mRNA treatment for chronic hepatitis B in a 2026 mouse study. Current interferon treatment helps only a small share of patients. The team packaged mRNA coding for a fused interferon protein inside tiny fat particles called lipid nanoparticles.
Earlier virus based delivery of the same fused protein had lowered hepatitis B markers safely in mice. A single vein injection of the new particles lowered virus antigens in a dose related way. One dose matched the effect of an approved interferon drug given under the skin. Safety checks showed no organ damage, only brief immune changes. Repeated doses raised antibodies against the human protein in mice, a problem the authors do not expect in people.
Catalog record
| CREATOR | Qunling Yang, Qiang Li, Jie Cao, Conglin Zhao, Mengxin Lu, Shuangshuang Sun, Mingsheng Chen, Chong Chen, Yuxian Huang, Shuai Tao, Liang Chen |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 35 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |